Trulieve Cannabis (TRLV) Stock Price, News & Analysis

Company Overview

Trulieve Cannabis Corp. is a vertically integrated cannabis company that cultivates, processes, manufactures and sells medical and adult-use cannabis products. Its product portfolio includes flower, pre-rolls, concentrates, edibles, tinctures, capsules and topical products, marketed under the Trulieve brand and other affiliated brands.

The company sells its products through a network of company-operated dispensaries and, where permitted, through wholesale and other distribution channels. Trulieve has established operations in several U.S. cannabis markets, including Florida, Arizona, Pennsylvania, Ohio, Connecticut, Massachusetts and West Virginia. Its geographic footprint has expanded through organic growth and acquisitions, including the 2021 acquisition of Harvest Health & Recreation.

Trulieve was founded in 2015 and initially focused on Florida's medical cannabis market before expanding into additional states and adult-use markets. Kim Rivers has served as the company's chief executive officer and has been associated with its growth since its early development. Cannabis regulations vary by state, and the company's operations are subject to applicable state licensing and compliance requirements.

Key Stats

• Today's Range: $10.71 to $11.78
• 50-Day Range: $8.05 to $12.42
• 52-Week Range: $4.62 to $13.28
• Volume: 12.70 million shs
• Average Volume: 1.57 million shs
• Market Capitalization: $2.14 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.00
• Consensus Rating: Hold

Trulieve Cannabis Stock Analysis - MarketRank™

Trulieve Cannabis scored higher than 66% of companies evaluated by MarketBeat, and ranked 256th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

Trulieve Cannabis has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

Upside Potential

Trulieve Cannabis has a consensus price target of $15.00, representing about 34.7% upside from its current price of $11.13.

Amount of Analyst Coverage

Trulieve Cannabis has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 83.87%

Earnings Growth

Earnings for Trulieve Cannabis are expected to grow by 83.87% in the coming year, from $0.31 to $0.57 per share.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.78% of the float of Trulieve Cannabis has been sold short.

Short Interest Ratio / Days to Cover

Trulieve Cannabis has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Trulieve Cannabis has recently increased by 8.21%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Trulieve Cannabis does not currently pay a dividend.

Dividend Growth

Trulieve Cannabis does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.31

News Sentiment

Trulieve Cannabis has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Trulieve Cannabis this week, compared to 2 articles on an average week.

Search Interest

Only 4 people have searched for TRLV on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

8 people have added Trulieve Cannabis to their MarketBeat watchlist in the last 30 days. This is an increase of 700% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Trulieve Cannabis insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,051,085.00 in company stock.

Percentage Held by Insiders

3.79% of the stock of Trulieve Cannabis is held by insiders.

Percentage Held by Institutions

Trulieve Cannabis has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/07/2026
• Today: 9/19/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSE:TRLV
• CIK: 1754195
• Web: trulieve.com
• Phone: (850) 298-8866
• Fax: N/A
• Employees: 5,000
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Trulieve Cannabis: $15.00
• High Price Target: $15.00
• Low Price Target: $15.00
• Potential Upside/Downside: +34.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 192,570,000
• Free Float: 185,267,000
• Market Cap: $2.14 billion
• Optionable: N/A
• Beta: N/A